BRAF and non-small cell lung carcinoma: For example, in non-small cell lung cancer (NSCLC), targeted therapies are currently approved and preferred over cytotoxic chemotherapy for patients with sensitizing EGFR mutations1–4, ALK and ROS1 gene rearrangements5–8, and BRAF variants9.